FDA postpones anti-NGF meeting

FDA postponed the Arthritis Advisory Committee that had been scheduled for Sept. 13 to discuss safety issues possibly related to anti- nerve growth factor (NGF) compounds. The agency said it needs time to review large quantities of new information submitted by IND holders of anti-NGF candidates. The agency has not set a new meeting date. ...